#ASH18: Gilead posts impressive survival rates for Yescarta — but sales remain lean
A little more than a year after Yescarta was approved as the first CAR-T for third-line therapy in large B-cell lymphoma, researchers are still trying to determine what the median overall survival rate for patients is. It hasn’t been reached.
Basic subscription required
Unlock this story instantly and join 54,600+ biopharma pros reading Endpoints daily — and it's free.